A checkerboard method to evaluate interactions between drugs

Biochemical Pharmacology

Volumn 51, Issue 5, 1996, Pages 635-644

  Martinez Irujo, Juan J ^a   Villahermosa, Maria L ^a   Alberdi, Elena ^a   Santiago, Esteban ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

combination chemotherapy; drug interaction; interaction index; isobologram; median effect equation; synergism

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE RIBOSE; ALCOHOL DEHYDROGENASE; CARBOVIR; PHENANTHROLINE; ZIDOVUDINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CURVE FITTING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INTERACTION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL MODEL; MONONUCLEAR CELL; NONHUMAN; NONLINEAR SYSTEM; PRIORITY JOURNAL; REGRESSION ANALYSIS; TECHNIQUE; THEORETICAL STUDY;

EID: 0029965805     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(95)02230-9     Document Type: Article

References (29)

1. Berenbaum MC, What is synergy? Pharmacol Rev 41: 93-141, 1989.
2. Loewe S, The problem of synergism and antagonism of combined drugs. Arznei Forsch 3: 285-290, 1953.
3. Berenbaum, MC, A method for testing for synergy with any number of agents. J Infect Dis 137: 122-130, 1978.
4. Sühnel J, Evaluation of synergism or antagonism for the combined action of antiviral agents. Antivir Res 13; 23-40, 1990.
5. Chou TC and Talalay P, Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
6. Prichard MN and Shipman C, A three-dimensional model to analyze drug-drug interactions. Antivir Res 14; 181-206, 1990.
7. Webb JL, Enzyme and Metabolic Inhibitors, Vol 1, pp. 55-79, 488-512. Academic Press, New York, 1963.
8. Leatherbarrow RJ, GraFit Version 3.0. Erithacus Software Ltd., Staines, U.K., 1993.
9. Sühnel J, Zero interaction response surfaces, interaction functions and difference response surfaces for combinations of biologically active agents. Arzneim Forsch 42: 1251-1258, 1992.
10. Berenbaum MC, Correspondence re: W.R. Greco et al., Application of a new approach to the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res, 50:5318-5327. Cancer Res 52: 4558-4560, 1992.
11. Berenbaum MC, Correspondence re: W.R. Greco et al., Application of a new approach to the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res, 50:5318-5327. Cancer Res 52: 4558-4560, 1992.
12. Sühnel J, Correspondence re: W.R. Greco et al., Application of a new approach to the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res, 50: 5318-5327. Cancer Res 52: 4560-4561, 1992.
13. Sühnel J, Correspondence re: W.R. Greco et al., Application of a new approach to the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res, 50: 5318-5327. Cancer Res 52: 4560-4561, 1992.
14. Jekunen AP, Shalinsky DR, Hom DK, Albright KD, Heath D and Howell SB, Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro. Biochem Pharmacol 45: 2079-2085, 1993.
15. McClay EF, Albright KD, Jones JA, Christen RD and Howell SB, Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53: 1571-1576, 1993.
16. Leatherbarrow RJ, Use of non linear regression to analyze enzyme kinetic data: Application to situations of substrate contamination and background substraction. Anal Biochem 184: 274-278, 1990.
17. Eron JJ, Johnson VA, Merril DP, Chou TC and Hirsch MS, Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′-3′-dideoxycytidine in vitro. Antimicrob Agents Chemother 36: 1559-1562, 1992.
18. Ferrareso M, Rigotti P, Stepkowski SM, Chou TC and Kahan BD, Immunosuppressive effects of defibrotide. Transplantation 56: 928-933, 1993.
19. Gelpí JL, Avilés JJ, Busquets M, Imperial S, Mazo A, Cortés A, Halsall DJ and Holbrook JJ, A theoretical approach to the discrimination and characterization of the different classes of reversible inhibitors. J Chem Educ 70: 805-816, 1993.
20. Ukraincik K and Piknosh W, Microprocessor-based radioimmunoassay data analysis. Methods Enzymol 74: 497-508, 1981.
21. Unkelbach HD and Pöch G, Comparison of independence and additivity in drug combinations. Arneim Forsch 38: 1-6, 1988.
22. Yonetani T and Theorell H, Studies on liver alcohol dehydrogenase complexes. III. Multiple inhibition kinetics in the presence of two competitive inhibitors. Arch Biochem Biophys 106: 243-251, 1964.
23. Chou TC and Talalay P, Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Europ J Biochem 115: 207-216, 1981.
24. Chou TC and Talalay P, A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic system. J Biol Chem 252: 6438-6442, 1977.
25. Smith MS, Kessler JA, Rankin CD, Pagano JS, Kurtzberg J and Carter SG, Evaluation of synergy between carbovir and 3′-azido2′,3′-deoxythymidine for inhibition of human immunodeficiency virus type 1. Antimicrob Agents Chemother 37: 144-147, 1993.
26. Michaud JP, Gandolfi AJ and Brendel K, Toxic responses to defined chemical mixtures: Mathematical models and experimental designs. Life Sci 55: 635-651, 1994.
27. DeClerck E, HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 47: 155-169, 1994.
28. Buckheit RW, White EL, Germanydecker J, Allen LB, Ross LJ, Shannon WM, Janssen PAJ y Chirigos MA. Cell based and biochemical analysis of the anti HIV activity of combinations of 3′-azido-3′-deoxythymidine and analogues of TIBO. Antivir Chem Chemother 5: 35-42, 1994.
29. Greco WR, Park HS and Rustum YM, Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res 50: 5318-5327, 1990.